亚宝药业：SY-005项目新适应症获临床试验批准

Core Viewpoint - The company announced that its subsidiary, Suzhou Yabao Pharmaceutical Research Co., Ltd., received approval from the National Medical Products Administration for clinical trials of SY-005 injection for a new indication related to postoperative neurological deficits in brain glioma patients [1] Group 1: Product Development - SY-005 is an innovative recombinant protein that previously received approval for clinical trials targeting sepsis in November 2018, which is currently in Phase II clinical trials [1] - The newly approved indication for SY-005 injection focuses on addressing neurological deficits following brain glioma surgery [1]